Cargando…

Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells

Huntington's disease (HD) is a neurodegenerative condition characterized by pathology in the brain and peripheral tissues. Hyperactivity of the innate immune system, due in part to NFκB pathway dysregulation, is an early and active component of HD. Evidence suggests targeting immune disruption...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dobson, Lucianne, Träger, Ulrike, Farmer, Ruth, Hayardeny, Liat, Loupe, Pippa, Hayden, Michael R., Tabrizi, Sarah J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	HIGHLIGHTED ARTICLE
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982105/ https://www.ncbi.nlm.nih.gov/pubmed/26823290 http://dx.doi.org/10.1111/jnc.13553

Ejemplares similares

Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2017)

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease
por: Garcia-Miralles, Marta, et al.
Publicado: (2016)

Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling
por: Kramann, Nadine, et al.
Publicado: (2016)

Author Correction: Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2019)

Laquinimod reduces neuroaxonal injury through inhibiting microglial activation
por: Mishra, Manoj Kumar, et al.
Publicado: (2014)

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation
por: Colombo, Emanuela, et al.
Publicado: (2020)

A PET-CT study on neuroinflammation in Huntington’s disease patients participating in a randomized trial with laquinimod
por: Roussakis, Andreas-Antonios, et al.
Publicado: (2023)

Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study
por: Stasiolek, Mariusz, et al.
Publicado: (2015)

Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS
por: Engel, Sinah, et al.
Publicado: (2020)

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
por: Brück, Wolfgang, et al.
Publicado: (2012)

Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis
por: Moore, Spencer, et al.
Publicado: (2013)

Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Surveilling microglia dampens neuronal activity: operation of a purinergically mediated negative feedback mechanism
por: Illes, Peter, et al.
Publicado: (2021)

Glycogen and amyloid-beta: key players in the shift from neuronal hyperactivity to hypoactivity observed in Alzheimer's disease?
por: Bass, Britanny, et al.
Publicado: (2015)

Mutant Huntingtin Does Not Affect the Intrinsic Phenotype of Human Huntington’s Disease T Lymphocytes
por: Miller, James R. C., et al.
Publicado: (2015)

Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea
por: Li, Zuohong, et al.
Publicado: (2020)

Laquinimod Supports Remyelination in Non-Supportive Environments
por: Nyamoya, Stella, et al.
Publicado: (2019)

Mitochondria hyperactivity contributes to social behavioral impairments
por: Zhang, Yun, et al.
Publicado: (2020)

RNA-Seq of Huntington’s disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation
por: Miller, James R. C., et al.
Publicado: (2016)

Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review
por: Kolb-Sobieraj, Channa, et al.
Publicado: (2014)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

The expanding world of stem cell modeling of Huntington's disease: creating tools with a promising future
por: Ward, Jacqueline M, et al.
Publicado: (2012)

Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake
por: Gentile, Antonietta, et al.
Publicado: (2018)

Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity
por: Schulze-Topphoff, Ulf, et al.
Publicado: (2012)

Laquinimod in the treatment of multiple sclerosis: a review of the data so far
por: Thöne, Jan, et al.
Publicado: (2016)

Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model
por: Wilmes, Anna T., et al.
Publicado: (2018)

Targeting “bad” B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
por: Forsthuber, Thomas G., et al.
Publicado: (2016)

Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS
por: Rothhammer, Veit, et al.
Publicado: (2021)

Ferritin-induced NETs lead to cytokine storm in AOSD
por: Onuora, Sarah
Publicado: (2023)

A WIMSical approach to decoding DNA methylation in myeloid leukemia
por: Guryanova, Olga A, et al.
Publicado: (2014)

Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation
por: van Geffen, Chiel, et al.
Publicado: (2022)

Surrogate cytokine agonists: promising agents against COVID-19
por: Lin, Zemin, et al.
Publicado: (2022)

Intratumorally delivering cytokines via a universal and modular strategy
por: Zhang, Xinping, et al.
Publicado: (2023)

Targeted cytokine delivery: cell therapy to remodel the pre-metastatic niche
por: Morgan, Michael A., et al.
Publicado: (2021)

Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression
por: Varrin-Doyer, Michel, et al.
Publicado: (2016)

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree
por: Cutter, Gary R., et al.
Publicado: (2016)

Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model
por: Katsumoto, Atsuko, et al.
Publicado: (2018)

JAK/STAT Signalling in Huntington’s Disease Immune Cells
por: Träger, Ulrike, et al.
Publicado: (2013)

Cytokine nanosponges suppressing overactive macrophages and dampening systematic cytokine storm for the treatment of hemophagocytic lymphohistiocytosis
por: Wang, Honglan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a1b6kti4sjpcg50djbbm106eso